Related Experiment Video

Updated: Apr 16, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K

Novel therapeutic targets in rheumatoid arthritis

Marije I Koenders1, Wim B van den Berg1

  • 1Radboud University Medical Center, Experimental Rheumatology, Nijmegen, The Netherlands.

Trends in Pharmacological Sciences
|March 4, 2015
PubMed

Insights

Rheumatoid arthritis (RA) is an autoimmune disease impacting joints. Novel therapies targeting the Janus kinase (JAK) and T helper-17 (Th17) pathways show promise for better RA management.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and destruction.
  • Current treatments are insufficient for up to 30% of RA patients, highlighting the need for novel therapeutic targets.
  • The Janus kinase (JAK) and T helper-17 (Th17) pathways are implicated in RA pathogenesis.

Purpose of the Study:

  • To review the therapeutic potential of targeting the JAK and Th17 pathways in rheumatoid arthritis.
  • To discuss biologicals and small-molecule inhibitors that block these key inflammatory pathways.
  • To explore advances in combination therapy and biomarker screening for personalized RA treatment.

Main Methods:

  • Literature review of current research on JAK and Th17 pathways in RA.
  • Analysis of therapeutic strategies involving biologicals and small-molecule inhibitors.
  • Discussion of emerging combination therapies and biomarker applications.

Main Results:

  • The JAK and Th17 pathways represent promising targets for novel RA therapies.
  • Biologicals and small-molecule inhibitors targeting these pathways are under investigation.
  • Combination therapies and biomarkers are crucial for advancing personalized RA care.

Conclusions:

  • Targeting the JAK and Th17 pathways offers new avenues for managing rheumatoid arthritis.
  • Further research into combination therapies and biomarkers will enhance treatment efficacy and personalization.
  • These advancements hold potential for improved patient outcomes in RA.
Keywords:
IL-17JAKTh17rheumatoid arthritistherapeutic targets

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.5K
A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model11:03

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model

Published on: October 30, 2019

9.3K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
820
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
17.1K